Please assess the completion status of the following clinical trial:

Trial Title: Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 12 to 18 months on the day of inclusion.~* In good general health, without significant medical history.~* Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations.~* Subject and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.~* Completion of vaccinations according to the national immunization schedule.~Exclusion Criteria :~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response.~* Administration of any anti-viral within 2 months preceding V01.~* History of central nervous system disorder or disease, including seizures.~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination.~* Personal human immunodeficiency virus seropositivity in the blood sample taken at screening.~* Receipt of any JE vaccine or hepatitis A vaccine.~* Previous vaccination against flavivirus disease.~* History of flavivirus infection (confirmed either clinically, serologically or microbiologically)~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination.~* Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- JE-CV GPO MBP (Lot 1) (Type: EXPERIMENTAL): Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
- JE-CV GPO MBP (Lot 2) (Type: EXPERIMENTAL): Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
- JE-CV GPO MBP (Lot 3) (Type: EXPERIMENTAL): Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
- JE-CV WRAIR (Group 4) (Type: ACTIVE_COMPARATOR): Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
- Hepatitis A (Group 5) (Type: SHAM_COMPARATOR): Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).